Erythroplasia of Queyrat treated with imiquimod 5% cream - 09/08/11
, Maria Rita Nasca, MD, PhD, Rocco De Pasquale, MD
Reprint requests: Giuseppe Micali, MD, Clinica Dermatologica, Università di Catania, Piazza S. Agata La Vetere, 6, 95124, Catania, Italy.Catania, Italy
Abstract |
Imiquimod is an immune response–modifying agent with potent antiviral and antitumor activity effective in the treatment of various skin disorders, including in situ carcinoma of the skin (Bowen’s disease). The case of a 64-year-old man affected by an in situ carcinoma of the glans mucosa, namely erythroplasia of Queyrat, successfully treated with imiquimod 5% cream is described. Because the results of tests for human papillomavirus infection were negative in this case, we suggest that imiquimod may have acted through an antitumor effect mediated by cytokine activation. This compound may represent an alternative treatment in patients with erythroplasia of Queyrat, although the dosing schedule and treatment duration require further evaluation.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None identified. |
Vol 55 - N° 5
P. 901-903 - novembre 2006 Retour au numéro
Article précédent
- Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma
- Ka Lung Wu, Freerk Heule, King Lam, Pieter Sonneveld
- Three cases of lymphomatoid papulosis with a CD56+ immunophenotype
- Sandy Flann, Guy E. Orchard, E. Mary Wain, Robin Russell-Jones
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?